Palla Pharma Limited Overview
Palla Pharma, founded as TPI Enterprises by Jarrod Ritchie, was an Australian vertically integrated opiate manufacturer. It spanned the chain from contracted poppy cultivation and poppy-straw processing through to codeine phosphate active pharmaceutical ingredient (API) and tableted finished dosage forms (FDF). It was one of three licensed poppy processors in Australia and the only Australian-owned one. It described itself as one of six licensed opiate producers globally and one of three fully integrated suppliers from extraction to tableting. Its claimed differentiator was a proprietary, water-based alkaloid extraction process that it said was low-cost, needed a small workforce and was environmentally sustainable. From 2017 the company pursued a "move down the value chain" strategy. It acquired Vistin Pharma's Norwegian opiates and tableting business and later bought UK marketing authorisations so it could sell its own branded generics. Collapsing volumes, low opioid prices, COVID-driven cuts to elective surgery and rising losses led to administration in December 2021 and liquidation in 2022.
Company's own description (FY2020 annual report and 2020 ASX announcements). Palla Pharma described itself as a vertically integrated opiate manufacturer, from poppy straw through to tableting production. It said it had developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a novel water-based extraction technology. It called itself one of six licensed opiate producers globally and one of three fully integrated suppliers from opiate extraction to tableting. Data providers summarise the business as producing and distributing narcotic raw materials (NRM), APIs and FDF for pharmaceutical markets in Australia and Norway, plus poppy seed for culinary markets.
Independent characterisation. Palla was a sub-scale, capital-intensive commodity alkaloid processor trying to become a specialty generic-drug manufacturer. Its economic engine had three stages:
-
Upstream (Australia, Coolaroo, Victoria). Poppy straw was sourced from contracted growers in Australia and the Northern Hemisphere (the company referred to "Australian and Northern Hemisphere supply sources" and had grower contracts in Portugal). The straw was processed into NRM, an alkaloid-rich concentrate mainly of morphine and codeine. By-product poppy seed was sold into culinary markets.
-
Midstream (Norway, Kragerø). NRM was shipped from Melbourne to the Kragerø plant and converted into codeine phosphate API and pholcodine (a cough-suppressant opioid). The plant had come with the 2017 Vistin acquisition.
-
Downstream (Norway, Kragerø, and the UK market). API was granulated and tableted into finished dosage forms. These were sold first as contract manufacturing for third parties, and from 2020–21 under Palla-owned UK marketing authorisations (MAs) such as a 30/500 co-codamol caplet.
Revenue model. Almost entirely product sales. The mix was NRM and poppy seed (B2B commodity), API (B2B supply contracts, typically multi-year with minimum tonnages), contract tableting (CMO), and own-MA FDF sales to UK wholesalers. There was no subscription or licensing revenue of note. One FY2020 disclosure referred to the termination of a "non-opiate based supply agreement", meaning lower-margin non-opiate contract work had also existed, probably legacy Vistin CMO tableting.
Value-chain position. Palla was a supplier to generic-drug formulators, contract manufacturers and, through its own MAs, UK pharmaceutical wholesalers. Customers included "one of Europe's leading pharmaceutical contract manufacturing organisations" (2018 contract), an unnamed European codeine phosphate customer (2019), a major UK-based multinational (2020 tablet extension), Sterling Pharma Solutions (UK, 2016 manufacturing and supply deal), an unnamed "global pharmaceutical company" (A$30 million deal, 2016), and Weifa (Norway, inherited from the Vistin CMO business).
End markets. Prescription and over-the-counter analgesics (codeine and co-codamol), cough and cold (pholcodine, codeine linctus), and culinary poppy seed. Demand was tied to surgical volumes and acute pain prescribing, which is why COVID-related elective-surgery cancellations, particularly in the UK, became the proximate trigger for failure.
Strategy
Stated strategic themes (2019–2021 company communications):
-
"Move down the value chain." Capture margin at each stage from farm to pharmacy by converting low-cost NRM into API and then FDF.
-
Downstream, margin-accretive own-MA FDF sales. The FY2020 report emphasised a focus on Palla MA FDF sales, possibly carried out through partners. Imminent supply of Palla generic FDF using its own MAs was presented as the future earnings growth engine.
-
Capacity expansion. Kragerø codeine phosphate capacity expansion (2018–19). Plan to raise packaging capacity to more than 70 tonnes in calendar 2021, with targeted supply of 24 tonnes of codeine phosphate in tableted form.
-
Low-cost NRM supply. Use Victorian NRM plus Northern Hemisphere sourcing to improve crop and alkaloid yields.
-
Exit lower-margin non-opiate work (completed in 2020).
-
Portugal API plant and poppy growing (2017 plan; not confirmed as executed).
Initiatives in the final 24 months (Dec 2019 – Dec 2021): acquisition of 11 UK MAs; abandoned acquisition of a UK tablet manufacturer; A$8 million UK tablet contract extension; MA site transfer to Norway (approved Feb 2021); March 2021 entitlement offer; CEO change (Giles Moss); strategic review (late 2021), which ended in administration.
Medium-term targets and guidance: FY2019 revenue guidance of A$60 million or more (missed: actual A$54.7 million). 2H FY2020 earnings were guided to be "significantly stronger" with a "material uplift" for the full year (not achieved: FY2020 operating EBITDA loss of about A$15.8 million). No subsequent quantitative guidance was verified. ESG commitments: beyond describing the extraction process as environmentally sustainable, none were publicly disclosed.
Products & Services
Product-level revenue: not publicly disclosed.
Product Portfolio
| Segment | Product / offering | Description | Target customer | Launch / latest | Pricing / commercial model | Notes |
|---|---|---|---|---|---|---|
Australia | Narcotic Raw Material (NRM) – morphine/codeine-rich concentrate | Alkaloid concentrate extracted from poppy straw using the proprietary water-based process | API manufacturers worldwide; internal transfer to Norway | Core product since the TPI era; Victorian plant | B2B tonnage contracts; prices not disclosed | NRM and poppy-seed revenue fell A$4.2 million in FY2020 |
Australia | Culinary poppy seed | By-product seed sold into international food markets | Food ingredient distributors | Ongoing to 2021 | Commodity pricing | Reported together with NRM |
Australia | Other alkaloids (thebaine, oripavine, noscapine) | Patent filings reference these alkaloids | API makers | — | — | Commercial volumes not publicly disclosed |
Norway | Codeine phosphate API | Converted from NRM at Kragerø | European CMOs and generic formulators | Inherited from Vistin in 2017; capacity expanded 2018–19 | Multi-year contracts: at least 6 t/yr (2018, over A$9 million over 3 years); 24 t/yr (2019, at least US$25 million) | Core growth product 2018–19 |
Norway | Pholcodine API | Opioid cough suppressant | Cough-syrup formulators | Inherited from Vistin | — | Vistin's second key product |
Norway | Codeine phosphate granulate | Intermediate form for tableting | Formulators | 2019 contract allowed supply as API, granulate or tablets | Contracted | — |
Norway | Contract tablet manufacturing (CMO) | Tableting for third parties | UK multinational (270 million tablets, A$8 million, 2020–21); Weifa (legacy) | Ongoing | Per-tablet contract | A non-opiate contract was terminated in 2020, reducing revenue |
Norway / UK | Palla-owned MA FDF: co-codamol 30/500 caplets | Own-brand codeine/paracetamol caplet for the UK | UK wholesalers and pharmacy | Validation 2020; site transfer approval Feb 2021 | Branded generic; the company said MA sales roughly doubled revenue per unit (over A$1 million versus A$0.5 million sold as API on a comparable basis) | Flagship of the downstream strategy |
Norway / UK | Other acquired UK MAs (11 in total: 4 plus 7) | Codeine-based products bought from distressed UK customer | UK market | Acquired 1H 2020 | Branded generic | Individual product names not publicly disclosed |
Technology | Water-based extraction process | Proprietary poppy-straw extraction | Internal | Developed in the TPI era | Not licensed externally | Claimed to need 50–60 staff for 80 tonnes a year versus 100–150 at peers |
“—” = not publicly disclosed.
Financial Narrative
Data availability. Palla's last full-year audited accounts were for FY2020 (year ended 31 December 2020, released 19 March 2021). The last interim accounts covered 1H 2021. No FY2021 accounts were lodged: the administrators relied on exemptions from financial reporting under Part 2M.3, and ASX waivers were refused. Where possible, figures are cross-checked between the FY2020 annual report (via AspectHuntley), Market Index and Investing.com.
Income statement: notes and sources
Sources: FY2020 annual report (sales of A$21.9 million versus A$54.7 million; statutory loss of A$34,756,056 versus A$7,639,443; operating EBITDA loss up by A$15.5 million from A$0.3 million); Market Index (trading revenue, NPAT and abnormals). Gross profit is the analyst's estimate from the 1H 2019 gross margin of 34.6% on A$27.3 million plus aggregator 2H figures.
Half-year income statement: notes and sources
Sources: 1H2019 revenue and gross margin from Retail Pharmacy Magazine (company results); 1H2019 net income derived (FY2019 minus 2H2019); other periods from Investing.com. Note: Investing.com labels some periods as "12 months", but the values reconcile to half-years (for example, 1H2020 plus 2H2020 = A$22.1 million versus FY2020 sales of A$21.9 million), so they are treated as half-years here. 1H2019 underlying net loss was reported as A$2.3 million.
Balance sheet
Source: Investing.com. Cash and equivalents, total debt (short- and long-term split), net debt, goodwill and intangibles, and working capital: not publicly disclosed in retrieved sources. Net tangible assets per share were 34 cents at 30 June 2020, down 5.6% (Biotech Daily).
Equity fell by about 72% in 18 months (A$71.4 million to A$20.1 million) while liabilities rose by 64%. By June 2021 the company had lost most of the equity raised in October 2019 and March 2021. The write-down of acquired MAs and Norwegian assets is a likely driver of the large 1H 2021 loss, but the composition of that loss is not disclosed in the retrieved data.
Cash flow
Source: Investing.com (period labelling ambiguity noted in 6.2). Capex, free cash flow, dividends paid and buybacks: not separately disclosed. No dividends or buybacks were ever made.
Operating cash burn rose from about A$9 million a half in 2H2019 to over A$13 million a half in 2021. Financing inflows of A$11–14 million every half-year show the business depended entirely on repeated equity raisings and borrowings.
Ratios (derived by the analyst)
ROE, ROA and asset turnover for FY2020 use average equity (A$53.8 million) and average assets (A$78.5 million). ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage and cash conversion cycle: not publicly disclosed (debt and working-capital components unavailable). Interest coverage was negative in any case, since EBITDA was negative.
Commentary on trends, inflections and drivers
Peak and inflection (2019). FY2019 was the high-water mark: sales of A$54.7 million and a near-breakeven operating EBITDA (loss of A$0.3 million). This was driven by codeine phosphate API contracts, including the 24 t/yr European agreement, and tableting for a large UK customer. The company had guided to A$60 million or more and reported a "modest, maiden" half-year operating EBITDA profit in 1H 2019.
Collapse (2020). Revenue fell 60% as Palla deliberately exited lower-margin non-opiate contract work and as its largest UK customer suspended manufacturing. Palla supported that customer with working capital and bought its MAs, but the regulatory site transfer slipped to February 2021, leaving the Norwegian plant underused. COVID-19 cut elective-surgery volumes. Gross margin turned negative in 2H 2020. A A$1.0 million trade-receivables impairment was booked on API shipped in 2019 to the major customer. Abnormal items of A$15.1 million produced a statutory loss of A$34.8 million.
Terminal decline (2021). 1H 2021 revenue fell another 43% to A$7.1 million and the half-year loss was A$33.1 million. Labour costs in SG&A rose 19% to A$5.8 million even as revenue fell. The own-MA strategy did not deliver volume quickly enough, and the Omicron wave in late 2021 hit UK elective surgery again.
Overall. Palla never produced a full-year statutory profit in the period for which data is available. Revenue CAGR FY2019–FY2020 was -59.9%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Role | Fate |
|---|---|---|---|
Palla Pharma Limited | Australia | Listed parent; Coolaroo NRM and poppy-seed operations; head office | Liquidated; deregistered 7 Feb 2026 |
Palla Pharmaceuticals Pty Ltd | Australia | Australian subsidiary (named in auction materials as "In Liquidation") | Liquidated |
Palla Pharma Norway Holdings AS | Norway | Holding company for Norwegian operations | Sold 28 Mar 2022 to Norwegian consortium |
Palla Pharma Norway AS (formerly TPI Norway AS) | Norway | Kragerø API and FDF manufacturing | Sold 28 Mar 2022; continues trading privately |
Palla Pharma (UK) Limited | United Kingdom | UK commercial entity, likely holding UK MAs and wholesaling | Sold 19 Mar 2022 to Norwegian consortium |
Revenue by Segment and Segment Margins & Growth (%)
| Segment | 1H2020 | 1H2021 |
|---|---|---|
Norway segment revenue (AUD Mn) | 9.84 | 6.2 |
Australia segment revenue (AUD Mn) | 2.54 | 0.863 |
Total revenue (AUD Mn) | 12.33 | 7.06 |
Segment metric | 1H2021 | — |
Norway YoY growth (%) | -37 | — |
Australia YoY growth (%) | -66 | — |
Norway share of total revenue (%) | 87.8 | — |
Australia share of total revenue (%) | 12.2 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2019 | FY2020 |
|---|---|---|
Sales revenue (AUD Mn) | 54.69 | 21.91 |
Revenue growth YoY (%) | — | -59.9 |
Gross profit (AUD Mn, derived from half-years) | 17.4 | -1.06 |
Gross margin (%, derived) | 31.8 | -4.8 |
Operating EBITDA (AUD Mn) | -0.3 | -15.8 |
Statutory NPAT (AUD Mn) | -7.64 | -34.76 |
Abnormal / significant items (AUD Mn) | -2.04 | -15.1 |
NPAT before abnormals (AUD Mn) | -5.6 | -19.66 |
Net margin on sales (%, derived) | -14.0 | -158.6 |
Dividends per share (AUD) | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (1H2019–1H2021)
| Metric | 1H2019 | 2H2019 | 1H2020 | 2H2020 | 1H2021 |
|---|---|---|---|---|---|
Total revenue (AUD Mn) | 27.3 | 27.49 | 12.33 | 9.78 | 7.06 |
Gross profit (AUD Mn) | 9.45 | 7.95 | 1.79 | -2.85 | -3.5 |
Gross margin (%) | 34.6 | 28.9 | 14.5 | -29.1 | -49.6 |
Operating income (AUD Mn) | — | -2.08 | -8.02 | -24.7 | -32.17 |
Net income (AUD Mn) | -4.08 | -3.56 | -9.01 | -25.74 | -33.11 |
Balance Sheet and Financial Ratios (x)
| Metric | Dec2019 | Jun2020 | Dec2020 | Jun2021 |
|---|---|---|---|---|
Total assets (AUD Mn) | 89.57 | 86.17 | 67.42 | 49.89 |
Total liabilities (AUD Mn) | 18.16 | 24.43 | 31.3 | 29.82 |
Total equity (AUD Mn) | 71.41 | 61.74 | 36.12 | 20.07 |
Liabilities to equity (x, derived) | 0.25 | 0.40 | 0.87 | 1.49 |
Cash Flow
| Metric | 2H2019 | 1H2020 | 2H2020 | 1H2021 |
|---|---|---|---|---|
Operating cash flow (AUD Mn) | -9.47 | -5.44 | -14.78 | -13.35 |
Investing cash flow (AUD Mn) | -2.48 | -2.15 | 0.77 | -0.38 |
Financing cash flow (AUD Mn) | 11.69 | 7.37 | 12.53 | 13.93 |
Net change in cash (AUD Mn) | 0.11 | -0.37 | -1.41 | 0.29 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2020 |
|---|---|
ROE (%) | -64.6 |
ROA (%) | -44.3 |
Asset turnover (x) | 0.28 |
Revenue by Region
| Region | 1H2020 | 1H2021 |
|---|---|---|
Norway (AUD Mn) | 9.84 | 6.2 |
Australia (AUD Mn) | 2.54 | 0.863 |
Region | 1H2021 YoY growth (%) | — |
Norway | -37 | — |
Australia | -66 | — |
Share Price History
| Date | Price (AUD) | Context |
|---|---|---|
28 Oct 2015 | 3.45 | Director on-market purchase |
31 May 2016 | 3.10 | Director purchase |
Jul 2017 | 2.42 | After Vistin deal (+10%) |
1 Sep 2017 | 2.391 | Director purchase |
2 Mar 2018 | 1.36 | Director purchase |
16 Oct 2019 | 0.90 | Last trade before raise |
Oct 2019 | 0.70 | Placement and entitlement price |
26 May 2020 | 0.80 | After +12.7% day |
31 Aug 2020 | 0.80 | After 1H20 result (-11%) |
Mar 2021 | 0.50 | Entitlement price |
12 Apr 2021 | 0.476 | Director purchase |
9 Jun 2022 | 0 | Declared worthless |
Analyst Conclusions
Management guidance / consensus: not applicable. The entity has been liquidated and deregistered.
Bull case (as it stood in 2020–21, with hindsight)
-
Own-MA FDF economics: revenue per unit roughly double API, through owned UK MAs.
-
Contracted API base: at least US$25 million over 3 years plus over A$9 million over 3 years.
-
Strategic asset value: Kragerø proved saleable as a going concern and still operates.
Bear case (borne out)
-
Losses accelerated from -A$7.6 million to -A$34.8 million to -A$33.1 million per half while revenue fell by about 87% from the 2H2019 run-rate.
-
Equity eroded from A$71.4 million to A$20.1 million in 18 months, with operating cash burn above A$13 million per half.
-
Exogenous demand shocks (pandemic, low opioid prices) against a high fixed-cost, two-continent structure.
Monitorables for the next 12 months: for Palla Pharma Limited, none. For the successor Palla Pharma Norway AS (private): Norwegian annual accounts (Brønnøysund register), European codeine supply-security developments, and UK MA ownership.
Analyst verdict. Palla Pharma's failure illustrates the risks of a sub-scale commodity producer trying to buy its way into specialty margins without the balance sheet to survive the transition. The strategic logic was sound on paper: own low-cost NRM, convert it to API in Europe, and sell branded tablets under owned MAs to capture the whole margin stack. The 2017 Vistin acquisition at about 5.6x EBITDA gave TPI a real downstream platform, and 2019 showed what it could earn at volume: A$54.7 million of sales and a near-breakeven operating EBITDA.
The model was fragile, though. NRM was produced in Melbourne and converted in Kragerø, which doubled the fixed-cost base and tied up working capital in shipments of controlled substances. Revenue was concentrated, so when the largest UK customer faltered Palla absorbed its problems by buying its MAs, and then waited about a year for regulators to approve the manufacturing transfer. COVID-19 then cut the elective-surgery demand that drives codeine and co-codamol use, and opioid prices stayed low.
The numbers show the result. Sales fell 60% in FY2020, gross margin turned sharply negative, equity fell by 72% in 18 months, and the company depended on capital raises that retail investors increasingly declined. A founder-CEO exit in December 2020 and a new CEO in September 2021 came too late.
The administration outcome is instructive. No buyer would take on the Australian plant, and Coolaroo was closed and auctioned. The Norwegian business was bought by local investors and continues to trade, which suggests the downstream assets had standalone value while the Australian upstream operation was the stranded cost. For investors the lesson is clear: in licensed, oligopolistic industries, scale and a strong balance sheet matter more than process innovation. Shareholders lost everything; creditors were expected to recover between 6 and 84 cents in the dollar. The entity has now ceased to exist.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / education | Compensation |
|---|---|---|---|---|
Giles Moss | CEO | 1 Sep 2021 – administration | VP and GM Europe, GW Pharmaceuticals (to Jul 2021); also CEO of Sapient Therapeutics; University of Manchester (undergraduate), Henley Management College (MBA); more than 30 years of pharma commercial leadership | — |
Paul Sherman | CFO | 19 Oct 2021 – administration | — | — |
Brendan Middleton | CFO; interim CEO (Dec 2020 – Aug 2021) | 12 Apr 2017 – 19 Oct 2021 | — | — |
Jarrod Ritchie | Founder, MD and CEO | 5 Feb 2004 – 22 Dec 2020 | Founder; led the company for about 17 years | Not publicly disclosed in retrieved sources |
Craig Sweenie | Site Director, Norway (former) | — | Named in LinkedIn post by former employee | — |
Marit Risberg | Quality and Regulatory Director, Norway (former) | — | As above | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Ceased | Notes |
|---|---|---|---|---|
Simon Moore | — | 1 Jun 2016 | 23 May 2022 | Founder of Colinton Capital; former Carlyle country head; also a shareholder |
Stuart Black | Non-executive director | 7 Jun 2016 | 21 Apr 2022 | IBISWorld lists him as CEO, apparently in error. |
Sue MacLeman | Non-executive director | 27 Nov 2018 | 21 Apr 2022 | — |
Iain Ross | Non-executive director | 23 Dec 2020 | 21 Apr 2022 | Bought 75,000 shares at A$0.476 (about A$35,700) on 12 Apr 2021 |
Todd Barlow | Non-executive director | 18 Jun 2015 | 4 Feb 2021 | CEO of Washington H. Soul Pattinson (major shareholder) |
Peter Robinson | Chairman | 1 Feb 2013 | 1 May 2018 | Bought 25,000 shares at A$1.36 in Mar 2018 |
Jarrod Ritchie | Managing Director | 5 Feb 2004 | 22 Dec 2020 | Founder |
Major Shareholders
| Holder | Stake |
|---|---|
Other top-10 holders | Not publicly disclosed in retrieved sources |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning relative to Palla |
|---|---|---|
Tasmanian Alkaloids (Tasmania; owned by SK Capital alongside Noramco from 2016) | Australian poppy processing, NRM, thebaine/oripavine | Much larger Australian processor with established grower base |
Sun Pharmaceutical Industries (Tasmanian opiates business acquired from GSK, 2015) | Australian poppy processing, NRM and API | Integrated within a global generics major |
Noramco (US) | Opiate API | Large API supplier to the US market |
SpecGx / Mallinckrodt (US) | Opiate API and generics | Dominant US opioid API and generic supplier |
Macfarlan Smith (UK; formerly Johnson Matthey) | Opiate API, codeine, UK market | Direct UK and European API competitor |
Alcaliber (Spain) | Poppy cultivation, NRM, API | Integrated European competitor |
Francopia (France) | Opiate API | European API competitor |
Siegfried (Switzerland) | Controlled-substance APIs | Large CDMO with narcotics capability |
Government opium and alkaloid works, India (Ghazipur, Neemuch) | NRM from opium gum | State-run supply under the INCB traditional-supplier framework |
UK generic FDF makers (various) | Co-codamol and codeine tablets | Competitors for the own-MA strategy |
Recent Developments
The standard 18-month window (April 2025 – October 2026) has no corporate activity other than deregistration.



